{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-23-000012","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.268496+00:00","generated_at":"2026-06-18T21:17:55.300158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amphastar Q4 revenue $135M (+11.7% YoY); GAAP EPS $0.66; full-year revenue $499M (+14.0% YoY)","bullets":["Q4 2022 net revenue $135.0M vs $120.9M YoY; GAAP net income $33.9M ($0.66 diluted EPS) vs $19.8M ($0.39).","Full-year 2022 net revenue $499.0M vs $437.8M, GAAP net income $91.4M ($1.74) vs $62.1M ($1.25).","Adjusted non-GAAP Q4 EPS $0.73, full-year $1.97; growth driven by epinephrine, Primatene MIST, and glucagon.","CEO cites strongest quarter and anticipates multiple new product launches in 2023.","No forward guidance provided; financial comparisons are to prior-year periods."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-23-000012","json":"https://secwatch.observer/filing/0001297184-23-000012.json","markdown":"https://secwatch.observer/filing/0001297184-23-000012.md","text":"https://secwatch.observer/filing/0001297184-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/0001297184-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/amph-20230228x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:17:55.300158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"440edcbab956705eec268008977d9a7b314dd4ec","claim":"Amphastar Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2022 results: revenue $499.0 million, net income $91.4 million, EPS $1.74 per share.","evidence_excerpt":"Net revenues of $499.0 million for the fiscal year ● GAAP net income of $91.4 million, or $1.74 per share, for the fiscal year ● Adjusted non-GAAP net income of $103.2 million, or $1.97 per share, for the fiscal year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/0001297184-23-000012-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$499.0 million"},{"label":"Net income","value":"$91.4 million"},{"label":"EPS","value":"$1.74 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e760929ae38aef95392ae05c37e3075a9bcb7179","claim":"Amphastar Pharmaceuticals, Inc. reported the three months ended December 31, 2022 results: revenue $135.0 million, net income $33.9 million, EPS $0.66 per share.","evidence_excerpt":"Net revenues of $135.0 million for the fourth quarter ● GAAP net income of $33.9 million, or $0.66 per share, for the fourth quarter ● Adjusted non-GAAP net income of $37.6 million, or $0.73 per share, for the fourth quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/0001297184-23-000012-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$135.0 million"},{"label":"Net income","value":"$33.9 million"},{"label":"EPS","value":"$0.66 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}